Prevalence of multiple drug resistant clinical isolates of extended-spectrum beta-lactamase producing enterobacteriaceae in Southeast Iran

Iranian Journal of Medical Sciences

Volumn 35, Issue 2, 2010, Pages 101-108

  Mansouri, Shahla ^a   Abbasi, Samaneh ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antimicrobial resistance; Enterobacteriaceae; Inpatients; Outpatients

Indexed keywords

AMOXICILLIN; CEFALEXIN; CEFTAZIDIME; CEFTIZOXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CRITICALLY ILL PATIENT; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; INFECTION CONTROL; IRAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT; PREVALENCE; SEX DIFFERENCE; WARD;

EID: 85011655604     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006; 119: S20-8.
2. Karlowsky JA, Jones ME, Thornsberry C, et al. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1672-80.
3. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52: 813-21.
4. Sepehri GH, Meimandi MS. The quality of prescribing in general practice in Kerman, Iran. Int J Health Care Qual Assur Inc Leadersh Health Serv 2005; 18: 353-60.
5. Poole K. Resistance to beta-lactam antibiotics. Cell Mol Life Sci 2004; 61: 2200-23.
6. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-9.
7. Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum β-lactamase–producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002). Diag Microbiol Infect Dis 2005; 52: 323-9.
8. Ndugulile F, Jureen R, Harthug S, et al. Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania. BMC Infect Dis 2005; 5: 86.
9. Tasli H, Bahar IH. Molecular Characterization of TEM-and SHV-Derived Extended-Spectrum Beta-Lactamases in Hospital-Based Enterobacteriaceae in Turkey. Jpn J Infect Dis 2005; 58:162-7.
10. Mesa RJ, Blanc V, Blanch AR, et al. Extended- spectrum beta-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage). J Antimicrob Chemother 2006; 58: 211-5.
11. Winokur PL, Vonstein DL, Hoffman LJ, et al. Evidence for transfer of CMY-2 AmpC beta-lactamase plasmids between Escherichia coli and Salmonella isolates from food animals and humans. Antimicrob Agents Chemother 2001; 45: 2716-22.
12. Feizabadi MM, Etemadi G, Yadegarinia D, et al. Antibiotic-resistance patterns and frequency of extended-spectrum betalactamase-producing isolates of Klebsiella pneumoniae in Tehran. Med Sci Monit 2006; 12: BR362-5.
13. Mehrgan H, Rahbar M. Prevalence of extended- spectrum β-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran. Int J Antimicrob Agents 2008; 31: 147-51.
14. Shahcheraghi F, Moezi H, Feizabadi MM. Distribution of TEM and SHV betalactamase genes among Klebsiella pneumonia strains isolated from patients in Tehran. Med Sci Monit 2007; 13: BR247-50.
15. MacFaddin JF. Gram-Negative Enterobacteriaceae and other intestinal bacteria. In: McGrew L ed. Biochemical Tests for Identification of Medical Bacteria Philadelphia, USA: Lippincott Williams& Wilkins. 1980. p. 732-804.
16. Amsterdam D. Interpretive guidelines for susceptibility or resistance. In: Lorian V ed. Antibiotics In Laboratory Medicine: Lippincott Williams & Wilkins. 2005. p. 113-25.
17. Turnidge JD, Bell J M. Antimicrobial susceptibility on solid media. In: Lorian V ed. Antibiotics In Laboratory Medicine: Lippincott Williams & Wilkins. 2005. p. 8-60.
18. Miró E, Mirelis B, Navarro F, et al. Surveillance of extended-spectrum β-lactamases from clinical samples and faecal carriers in Barcelona, Spain. Br Soc Antimicrob Chemo 2005; 56: 1152-5.
19. Shah AA, Hasan F, Ahmed S, Hameed A. haracteristics, epidemiology and clinical importance of emerging strains of Gramnegative bacilli producing extendedspectrum beta-lactamases. Res Microbiol 2004; 155: 409-21.
20. Sader HS, Biedenbach DJ, Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn Microbiol Infect Dis 2003; 47: 361-4.
21. Andrade SS, Sader HS, Jones RN, et al. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines? Mem Inst Oswaldo Cruz 2006; 101: 741-8.
22. Chanal C, Bonnet R, De Champs C, et al. Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital. Antimicrob Agents Chemother 2000; 44: 1930-5.
23. McGowan JE Jr, Hall EC, Parrott PL. Antimicrobial susceptibility in gram-negative bacteremia: are nosocomial isolates really more resistant? Antimicrob Agents Chemother 1989; 33: 1855-9.
24. Mansouri S, Shareifi S. Antimicrobial resistance pattern of Escherichia coli causing urinary tract infections, and that of human fecal flora, in the southeast of Iran. Microb Drug Resist 2002; 8: 123-8.
25. Bell JM, Chitsaz M, Turnidge JD, et al. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program. J Clin Microbiol 2007; 45: 1478-82.
26. Giske CG, Sundsfjord AS, Kahlmeter G, et al. Redefining extended-spectrum betalactamases: balancing science and clinical need. J Antimicrob Chemother 2009; 63: 1-4.
27. de Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother 2000; 45: 537-9.
28. Mirsalehian A, Akbari-Nakhjavani F, Peymani A, et al. Prevalence of Extended Spectrum β-Lactamase-Producing Enterobacteriaceae by Phenotypic and Genotypic Methods in Intensive Care Units in Tehran, Iran. DARU 2008; 16: 169-73.
29. Schwaber MJ, Raney PM, Rasheed JK, et al. Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae. J Clin Microbiol 2004; 42: 294-8.